Search icon

Celebrity

07th Apr 2022

Love Island’s Kaz receives “hate messages” after Ashley Cain dating rumours

Sarah McKenna Barry

This is awful.

Kaz Crossley, who appeared on Love Island in 2018, has said that she’s received online abuse after being linked to Ashley Cain.

Kaz held a Q&A on her Instagram the other day and when a fan asked if she was seeing Ashley, she shared that she was subject to “hate messages” after they did a photo shoot together.

“We are friends but after our work shoot the other day I’ve been getting hate messages saying I’m trying to get with him,” she said.

“I’ve always supported his cause and likewise him with my kids in Thailand. People are so quick to tear each other down it’s sad.”

A few weeks ago, Ashley Cain announced that he was no longer in a relationship with Safiyya Vorajee. The pair were parents to baby Azaylia who passed away last year after she was diagnosed with acute myeloid leukemia.

In a post on Instagram, Ashley wrote: “After a devastating and heartbreaking year, Safiyya and I decided to separate a few months ago.

https://www.instagram.com/p/CbnT4eBN20u/

“This was an incredibly tough decision which we needed to keep to ourselves for some time to give us the opportunity to figure out our own journey privately.

“The past few months have demonstrated that we remain the closest of friends, spending time together everyday and that we will love, care and support each other forever.

“We are bonded by our powerful journey together, by the eternal love we have for our daughter and our passionate commitment to her foundation.”

Safiyya also commented on the break up on Instagram, saying she was “feeling low” ahead of the split being announced.

The pair had established the Azaylia Foundation in honour of their late daughter. According to the website, the foundation “supports children fighting cancer by helping them access treatment not readily available from the NHS, while at the same time working with cancer research and medical institutions to advance early diagnosis and accelerate the availability of new treatments in the UK.”